If you’re eyeing Novavax (NVAX) today, you’re not alone, and the reason is clear. Investors are buzzing after the company announced a refinancing deal that pushes out most of its convertible debt from ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children younger than 5 years old, a move that would add another barrier ...

Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax has experienced a significant decline in its stock price, dropping by 19.26% over the past week. This downturn comes despite recent positive developments, including a $175 million milestone ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

The number of people with COVID-19 in the U.S. is low but increasing, according to Centers for Disease Control and Prevention (CDC) data released Friday. COVID-19 is trending up in many mid-Atlant… ...